Literature DB >> 30108175

HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.

Wenjing Li1,2, Xiahui Xiong1, Amro Abdalla1, Salvador Alejo1, Linyu Zhu1, Fei Lu2, Hong Sun3.   

Abstract

The MET proto-oncogene-encoded receptor tyrosine kinase (MET) and AXL receptor tyrosine kinase (AXL) are independently operating receptor tyrosine kinases (RTKs) that are functionally associated with aggressive and invasive cancer cell growth. However, how MET and AXL regulate the migratory properties of cancer cells remains largely unclear. We report here that the addition of hepatocyte growth factor (HGF), the natural ligand of MET, to serum-starved human glioblastoma cells induces the rapid activation of both MET and AXL and formation of highly polarized MET-AXL clusters on the plasma membrane. HGF also promoted the formation of the MET and AXL protein complexes and phosphorylation of AXL, independent of AXL's ligand, growth arrest-specific 6 (GAS6). The HGF-induced MET-AXL complex stimulated rapid and dynamic cytoskeleton reorganization by activating the small GTPase RAC1, a process requiring both MET and AXL kinase activities. We further found that HGF also promotes the recruitment of ELMO2 and DOCK180, a bipartite guanine nucleotide exchange factor for RAC1, to the MET-AXL complex and thereby stimulates the RAC1-dependent cytoskeleton reorganization. We also demonstrated that the MET-AXL-ELMO2-DOCK180 complex is critical for HGF-induced cell migration and invasion in glioblastoma or other cancer cells. Our findings uncover a critical HGF-dependent signaling pathway that involves the assembly of a large protein complex consisting of MET, AXL, ELMO2, and DOCK180 on the plasma membrane, leading to RAC1-dependent cell migration and invasion in various cancer cells.
© 2018 Li et al.

Entities:  

Keywords:  Ras-related C3 botulinum toxin substrate 1 (Rac1); cancer; cell invasion; cell migration; cell signaling; glioblastoma; guanine nucleotide exchange factor (GEF); receptor tyrosine kinase

Mesh:

Substances:

Year:  2018        PMID: 30108175      PMCID: PMC6177597          DOI: 10.1074/jbc.RA118.003063

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion.

Authors:  Michael J Jarzynka; Bo Hu; Kwok-Min Hui; Ifat Bar-Joseph; Weisong Gu; Takanori Hirose; Lisa B Haney; Kodi S Ravichandran; Ryo Nishikawa; Shi-Yuan Cheng
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 2.  GEF what? Dock180 and related proteins help Rac to polarize cells in new ways.

Authors:  Jean-François Côté; Kristiina Vuori
Journal:  Trends Cell Biol       Date:  2007-08-31       Impact factor: 20.808

3.  Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for met-triggered cortical neuron migration.

Authors:  Joseph Segarra; Laurent Balenci; Thijs Drenth; Flavio Maina; Fabienne Lamballe
Journal:  J Biol Chem       Date:  2005-12-16       Impact factor: 5.157

Review 4.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

Review 5.  Life at the leading edge.

Authors:  Anne J Ridley
Journal:  Cell       Date:  2011-06-24       Impact factor: 41.582

Review 6.  Met receptor: a moving target.

Authors:  Michael J Clague
Journal:  Sci Signal       Date:  2011-09-06       Impact factor: 8.192

7.  Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Authors:  Falko Hochgräfe; Luxi Zhang; Sandra A O'Toole; Brigid C Browne; Mark Pinese; Ana Porta Cubas; Gillian M Lehrbach; David R Croucher; Danny Rickwood; Alice Boulghourjian; Robert Shearer; Radhika Nair; Alexander Swarbrick; Dana Faratian; Peter Mullen; David J Harrison; Andrew V Biankin; Robert L Sutherland; Mark J Raftery; Roger J Daly
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

8.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

9.  Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells.

Authors:  A J Ridley; P M Comoglio; A Hall
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

10.  GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance.

Authors:  Christine Baumann; Axel Ullrich; Robert Torka
Journal:  Mol Oncol       Date:  2017-07-26       Impact factor: 6.603

View more
  15 in total

1.  A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation.

Authors:  Akash Sabarwal; Johannes Wedel; Kaifeng Liu; David Zurakowski; Samik Chakraborty; Evelyn Flynn; David M Briscoe; Murugabaskar Balan; Soumitro Pal
Journal:  Carcinogenesis       Date:  2022-05-19       Impact factor: 4.741

2.  FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma.

Authors:  Mariana Cooke; Gabriel Kreider-Letterman; Martin J Baker; Suli Zhang; Neil T Sullivan; Evgeniy Eruslanov; Martin C Abba; Silvia M Goicoechea; Rafael García-Mata; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2021-11-02       Impact factor: 9.995

Review 3.  State of the structure address on MET receptor activation by HGF.

Authors:  Edmond M Linossi; Gabriella O Estevam; Masaya Oshima; James S Fraser; Eric A Collisson; Natalia Jura
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

4.  TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma.

Authors:  Wei Zhang; Xiaoxiao Zheng; Shangzhi Xie; Shufen Zhang; Jiayan Mao; Ying Cai; Xuemei Lu; Wei Chen; Haibin Ni; Liping Xie
Journal:  Mol Med Rep       Date:  2020-06-16       Impact factor: 2.952

Review 5.  Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase.

Authors:  Laurie G Hudson; Jennifer M Gillette; Huining Kang; Melanie R Rivera; Angela Wandinger-Ness
Journal:  Cancers (Basel)       Date:  2018-09-27       Impact factor: 6.639

6.  Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering.

Authors:  Wenjing Li; Adam Dick; Fei Lu; Hui Zhang; Hong Sun
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

7.  Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.

Authors:  Takahito Hara; Akiko Kimura; Tohru Miyazaki; Hiroshi Tanaka; Megumi Morimoto; Katsuhiko Nakai; Junpei Soeda
Journal:  Biochem Biophys Rep       Date:  2020-01-17

Review 8.  AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.

Authors:  Siyang Yan; Niels Vandewalle; Nathan De Beule; Sylvia Faict; Ken Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Kim De Veirman
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

Review 9.  The Role of Rho GTPases in Motility and Invasion of Glioblastoma Cells.

Authors:  Houssam Al-Koussa; Oula El Atat; Leila Jaafar; Hagop Tashjian; Mirvat El-Sibai
Journal:  Anal Cell Pathol (Amst)       Date:  2020-01-31       Impact factor: 2.916

10.  Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA.

Authors:  Xingyu Li; Zhiqiang Li; Hongwei Zhu; Xiao Yu
Journal:  Biomed Res Int       Date:  2020-11-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.